Clinical characteristics and social burden of menstrual migraine in Japan: an online-based cross-sectional questionnaire study
- PMID: 41299238
- PMCID: PMC12659224
- DOI: 10.1186/s10194-025-02219-5
Clinical characteristics and social burden of menstrual migraine in Japan: an online-based cross-sectional questionnaire study
Abstract
Background: Menstrual migraine (MM) is a distinct and burdensome subtype of migraine; however, comprehensive data on its clinical and social impact among Japanese females remain limited. Therefore, we aimed to clarify the clinical characteristics and social burden of MM in Japan.
Methods: A cross-sectional, population-based web survey was conducted among Japanese females (≥ 18 years) with regular menstruation who were diagnosed with migraine. Participants were classified into MM and non-MM groups. Clinical parameters assessed between MM and non-MM included pain intensity, pain duration, and headache frequency during the perimenstrual period (-2 days to + 2 days of menstruation onset). Social burden was evaluated using the Migraine Disability Assessment (MIDAS), Migraine Interictal Burden Scale (MIBS-4), Migraine-Specific Quality of Life Questionnaire (MSQ), and Work Productivity and Activity Impairment for Migraine (WPAI-M). These were compared between MM and non-MM, adjusting for potential confounders through inverse probability of treatment weighting using propensity scores.
Results: Of 266,392 screened patients, 4,592 were included in MM and 5,174 in non-MM. The mean age was 36.8 ± 8.0 years in MM and 35.5 ± 8.3 years in non-MM. MM patients experienced higher pain intensity and longer pain duration than non-MM during both perimenstrual and non-perimenstrual periods (perimenstrual periods: -2 days to + 1 day of menstruation onset: all p < 0.001 for both, +2 days of menstruation onset: intensity, p = 0.003, duration, p = 0.046; non-perimenstrual period: intensity, p < 0.001, duration, p = 0.005). MM exhibited higher MIDAS and MIBS-4 scores (both p < 0.001) and lower MSQ scores (restriction, interference, emotion: all p < 0.001), indicating greater disability and reduced quality of life. Among WPAI-M scores, presenteeism, overall work and activity impairment, were also higher in MM vs non-MM (all p < 0.001). MM demonstrated increased usage (MM: 54.0% [1,088/2,015]; non-MM: 24.0% [169/705]) and broader type of medications (MM: 13.2% [265/2,015]; non-MM: 7.1% [50/705]) during the perimenstrual period, particularly non-steroidal anti-inflammatory drugs (MM: 51.4% [801/1,557]; non-MM: 45.4% [636/1,402]).
Conclusions: This study highlights the significant burden of MM, demonstrating increased pain intensity, longer pain duration and higher headache frequency during perimenstrual period, accompanied by a concurrent increase in social burden compared to non-MM. These findings underscore the impact of clinical severity and social burden of MM in Japanese females.
Keywords: Cross-sectional study; Menstrual migraine; Menstrually related migraine; Real-world evidence; Social burden.
© 2025. The Author(s).
Conflict of interest statement
Declarations. Ethics approval and consent to participate: The study data were managed in accordance with Japan’s Personal Information Protection Law. The study was conducted following approval from the ethics committee of the MINS (a specified nonprofit organization; approval ID: MINS-REC-240229). Patient consent was obtained before study participation, and participants were allowed to withdraw their consent at any time by contacting the Macromill Monitor Support System without disclosing the reason. Consent for publication: Not applicable. Competing interests: TT is a consultant/advisor and/or serves on advisory boards for Eli Lilly, Otsuka, Amgen, Pfizer, and Teijin; has received speaker honoraria from Daiichi Sankyo, Eli Lilly, Otsuka, Amgen, Sawai, Eisai, and Takeda; and has received grants/funding from Eli Lilly, Pfizer, and Tsumura outside the submitted work. KI has no competing interests to disclose. RY, KT, TK, and MI are employees of Pfizer Japan Inc. KT and MI are shareholders of Pfizer Inc.
Figures
References
-
- Silberstein S, Merriam G (1999) Sex hormones and headache 1999 (menstrual migraine). Neurology 53:S3–13. - PubMed
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
